Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 145.21M P/E - EPS this Y 4.50% Ern Qtrly Grth -
Income -39.77M Forward P/E 2.23 EPS next Y 157.10% 50D Avg Chg -23.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -23.00%
Dividend N/A Price/Book 1.47 EPS next 5Y - 52W High Chg -47.00%
Recommedations 2.00 Quick Ratio 4.31 Shares Outstanding 180.72M 52W Low Chg 19.00%
Insider Own 6.81% ROA -24.74% Shares Float 158.25M Beta 1.62
Inst Own 17.00% ROE -41.49% Shares Shorted/Prior 12.53M/12.28M Price 0.91
Gross Margin - Profit Margin - Avg. Volume 2,028,708 Target Price 4.67
Oper. Margin - Earnings Date Dec 27 Volume 1,696,404 Change -4.26%
About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Citius Pharmaceuticals, Inc. News
08:03 AM Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval
11/22/24 Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split
11/18/24 Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering
11/15/24 Citius Pharmaceuticals Announces $3 Million Registered Direct Offering
11/11/24 Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors
09/05/24 Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
09/05/24 Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
08/13/24 Sidoti Events, LLC's Virtual August Micro-Cap Conference
08/13/24 Citius merges oncology subsidiary with TenX Keane
08/12/24 Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update
08/12/24 Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.
08/12/24 Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments
08/09/24 TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update
08/08/24 Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin Cancer Drug A Year After FDA Rejection
08/08/24 Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
08/05/24 Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.
08/05/24 TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals
07/20/24 When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Turn A Profit?
07/18/24 Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
07/17/24 Analysts Hunt for Undervalued Biotech Stocks